Malaria continues to pose a significant global health threat, with 282 million cases reported in 2024, marking a 3% increase from the previous year. According to Dr. Jane M. Carlton, director of the Johns Hopkins Malaria Research Institute, the disease remains one of the deadliest infectious diseases in human history. The World Health Organization (WHO) reported 610,000 malaria-related deaths in 2024, raising concerns about the growing resistance to antimalarial drugs, particularly artemisinin, which is crucial for treatment. Resistance has been confirmed in at least eight African countries, while Anopheles mosquitoes are becoming immune to insecticides used on bed nets. Although new vaccines RTS,S and R21 have been introduced, they are not completely effective and require multiple doses, posing logistical challenges in poorer regions. Carlton emphasizes the importance of a comprehensive strategy that includes these vaccines, new bed nets, and emerging treatments like GanLum, the first new drug class for malaria in over 25 years. She advocates for intensified efforts to eliminate malaria, stating that achieving this goal is within reach.